LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 3 of 15: Cell count and relative growth within biological replicate 3. - Dataset (ID:20239)
Download: Excel (XLSX), Comma-separated (CSV)
Cell | Small Molecule | Small Mol Concentration | Small Mol Conc Unit | LJP Library Plate | Replicate | Assay Well | Timepoint | Timepoint Unit | Total Cell Count Before Treatment | Total Cell Count After Treatment | Total Control Cell Count | Relative Cell Count | Relative Growth Rate After Treatment |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
SK-BR-3 | Dasatinib | 10.0 | uM | LJP5 | 3 | D01 | 72 | hr | 1401 | 2000 | 4223 | 0.4736 | 0.2121 |
SK-BR-3 | Nilotinib | 10.0 | uM | LJP5 | 1 | N13 | 72 | hr | 1401 | 2115 | 4223 | 0.5008 | 0.2529 |
SK-BR-3 | QL-XII-47 | 10.0 | uM | LJP6 | 3 | O19 | 72 | hr | 1401 | 1192 | 4223 | 0.2823 | -0.0743 |
SK-BR-3 | Ruxolitinib | 10.0 | uM | LJP5 | 3 | O13 | 72 | hr | 1401 | 3813 | 4223 | 0.9029 | 0.8547 |
SK-BR-3 | OSI-027 | 0.04 | uM | LJP6 | 3 | E12 | 72 | hr | 1401 | 3026 | 4223 | 0.7165 | 0.5757 |
SK-BR-3 | JNK-9L | 0.12 | uM | LJP6 | 2 | K23 | 72 | hr | 1401 | 3306 | 4223 | 0.7828 | 0.6750 |
SK-BR-3 | Seliciclib | 0.04 | uM | LJP5 | 3 | J06 | 72 | hr | 1401 | 4492 | 4223 | 1.0637 | 1.0953 |
SK-BR-3 | Afatinib | 0.12 | uM | LJP6 | 2 | G23 | 72 | hr | 1401 | 1378 | 4223 | 0.3263 | -0.0083 |
SK-BR-3 | Dasatinib | 0.37 | uM | LJP5 | 2 | D04 | 72 | hr | 1401 | 4491 | 4223 | 1.0634 | 1.0950 |
SK-BR-3 | Geldanamycin | 1.11 | uM | LJP6 | 3 | O03 | 72 | hr | 1401 | 1331 | 4223 | 0.3152 | -0.0250 |
SK-BR-3 | Lapatinib | 3.33 | uM | LJP6 | 1 | M20 | 72 | hr | 1401 | 1560 | 4223 | 0.3694 | 0.0562 |
SK-BR-3 | Foretinib | 10.0 | uM | LJP5 | 1 | H07 | 72 | hr | 1401 | 1406 | 4223 | 0.3329 | 0.0016 |
SK-BR-3 | SNS-032 | 0.04 | uM | LJP6 | 1 | H18 | 72 | hr | 1401 | 2692 | 4223 | 0.6375 | 0.4574 |
SK-BR-3 | XMD11-85h | 0.04 | uM | LJP6 | 1 | P24 | 72 | hr | 1401 | 3393 | 4223 | 0.8034 | 0.7058 |
SK-BR-3 | Ruxolitinib | 0.04 | uM | LJP5 | 1 | O18 | 72 | hr | 1401 | 3818 | 4223 | 0.9041 | 0.8564 |
SK-BR-3 | Momelotinib | 0.37 | uM | LJP5 | 3 | P10 | 72 | hr | 1401 | 4150 | 4223 | 0.9827 | 0.9741 |
SK-BR-3 | JW-7-24-1 | 3.33 | uM | LJP6 | 3 | B20 | 72 | hr | 1401 | 2240 | 4223 | 0.5304 | 0.2972 |
SK-BR-3 | PHA-793887 | 10.0 | uM | LJP6 | 3 | E19 | 72 | hr | 1401 | 864 | 4223 | 0.2046 | -0.1905 |
SK-BR-3 | Withaferin A | 0.04 | uM | LJP5 | 2 | G18 | 72 | hr | 1401 | 4109 | 4223 | 0.9730 | 0.9596 |
SK-BR-3 | JW-7-24-1 | 3.33 | uM | LJP6 | 1 | B20 | 72 | hr | 1401 | 2168 | 4223 | 0.5134 | 0.2717 |